REFORM OF CANCER DRUGS FUND Cancer Drugs Fund: the bigger picture

被引：0
|
作者：
Longson, Carole M. [1 ]
Landells, Linda J. [1 ]
George, Elisabeth [1 ]
Boysen, Meindert [1 ]
Dillon, Andrew [1 ]
机构：
[1] Natl Inst Hlth & Care Excellence, Manchester M1 4BT, Lancs, England
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 355卷
关键词：
D O I：
10.1136/bmj.i5644
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Which way now for the Cancer Drugs Fund?
    Jack, Andrew
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
  • [22] Cancer Drugs Fund 2.0: A Missed Opportunity?
    Christopher McCabe
    Ash Paul
    Greg Fell
    Mike Paulden
    PharmacoEconomics, 2016, 34 : 629 - 633
  • [23] Cutbacks at England's Cancer Drugs Fund
    不详
    CANCER DISCOVERY, 2015, 5 (04) : 338 - 339
  • [24] THE CANCER DRUGS FUND: THE EVOLVING ASSESSMENT PROCESS
    Carroll, M., V
    Satherley, A.
    Miller, P. S.
    VALUE IN HEALTH, 2016, 19 (07) : A757 - A757
  • [25] Cancer Drugs Fund 2.0: A Missed Opportunity?
    McCabe, Christopher
    Paul, Ash
    Fell, Greg
    Paulden, Mike
    PHARMACOECONOMICS, 2016, 34 (07) : 629 - 633
  • [26] A mixed methods study on the prioritisation of cancer and access to cancer drugs: the Cancer Drugs Fund in England
    Chamberlain, Charlotte
    Owen-Smith, Amanda
    Donovan, Jenny L.
    Hounsome, Luke
    Collin, Simon M.
    Hollingworth, William
    LANCET, 2015, 386 : S17 - S17
  • [27] NICE recommends dropping two drugs from Cancer Drugs Fund
    Hawkes, Nigel
    BMJ-BRITISH MEDICAL JOURNAL, 2016, 354
  • [28] THE IMPACT OF CANCER DRUGS FUND REFORMS ON REIMBURSEMENT OF ONCOLOGY DRUGS IN THE UK
    Macaulay, R.
    Dave, K.
    Walsh, S. C.
    VALUE IN HEALTH, 2017, 20 (09) : A461 - A461
  • [29] Discussion: The carbon fund in the bigger picture
    Barrett, S
    GLOBAL PUBLIC POLICIES AND PROGRAMS: IMPLICATIONS FOR FINANCING AND EVALUATION, 2001, : 79 - 82
  • [30] The Cancer Drugs Fund in Practice and Under the New Framework
    Celia Sabry-Grant
    Kinga Malottki
    Alexander Diamantopoulos
    PharmacoEconomics, 2019, 37 : 953 - 962
12345